Skip to content
SCA Pharma
SCA Pharma
  • Why Choose SCA Pharma?
    • State of the Art Facilities
    • Our Leadership
    • Resources
    • 503B Supplier Guide
  • Leading 503B Solutions
    • Quality
      • Quality Standards
      • Pharmaceutical Quality System (PQS)
    • Products
  • News and Events
    • Press Releases
    • Tradeshows & Events
    • SCA Pharma Blog
  • Customer Portal
  • Careers
  • Contact Us
  • Why Choose SCA Pharma?
    • State of the Art Facilities
    • Our Leadership
    • Resources
    • 503B Supplier Guide
  • Leading 503B Solutions
    • Quality
      • Quality Standards
      • Pharmaceutical Quality System (PQS)
    • Products
  • News and Events
    • Press Releases
    • Tradeshows & Events
    • SCA Pharma Blog
  • Customer Portal
  • Careers
  • Contact Us

Daily Archives: April 12, 2022

FDA Announces Glycopyrrolate Will Not Be Included on 503B Bulks List

503B Outsourcing, FDA, NewsBy Jennifer LupascuApril 12, 2022

On January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future on the FDA’s drug shortage list. Glycopyrrolate is not currently on the drug shortage list.…

  • Careers
Footer
Go to Top